Vimentin mouse monoclonal Antibody | Affinity Biosciences

Product:	Vimentin mouse monoclonal Antibody
Catalog:	BF8006
Description:	Mouse monoclonal antibody to Vimentin
Application:	WB IHC IF/ICC
Cited expt.:	WB, IHC, IF/ICC
Reactivity:	Human, Mouse, Rat
Mol.Wt.:	53kDa; 54kD(Calculated).
Uniprot:	P08670
RRID:	AB_2847777

View similar products>>

Blocking peptides are peptides that bind specifically to the target antibody and block antibody binding. These peptide usually contains the epitope recognized by the antibody. Antibodies bound to the blocking peptide no longer bind to the epitope on the target protein. By comparing the staining from the blocked antibody versus the antibody alone, one can see which staining is specific.

Size	Price	Inventory
50ul	$250	In stock
100ul	$350	In stock
200ul	$450	In stock

Lead Time: Same day delivery

For pricing and ordering contact:
Local distributors

Related Downloads

MSDS

Data Sheet

COA

Protocols

WB Handbook

IHC Protocol

IF/ICC Protocol

Product Info

Source:

Mouse

Application:

WB 1:500-1:3000, IHC 1:50-1:200, IF/ICC 1:100-1:500
*The optimal dilutions should be determined by the end user. For optimal experimental results, antibody reuse is not recommended.
*Tips:

WB: For western blot detection of denatured protein samples. IHC: For immunohistochemical detection of paraffin sections (IHC-p) or frozen sections (IHC-f) of tissue samples. IF/ICC: For immunofluorescence detection of cell samples. ELISA(peptide): For ELISA detection of antigenic peptide.

Reactivity:

Human,Mouse,Rat

Clonality:

Monoclonal [AFfirm079]

Specificity:

Vimentin antibody detects endogenous levels of total Vimentin.

RRID:

AB_2847777
Cite Format: Affinity Biosciences Cat# BF8006, RRID:AB_2847777.

Conjugate:

Unconjugated.

Purification:

Affinity-chromatography.

Storage:

Mouse IgG1 in phosphate buffered saline (without Mg2+ and Ca2+), pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol. Store at -20 °C. Stable for 12 months from date of receipt.

Alias:

Fold/Unfold

CTRCT30; Epididymis luminal protein 113; FLJ36605; HEL113; VIM; VIME_HUMAN; Vimentin;

Immunogens

Immunogen:

Purified recombinant fragment of human Vimentin expressed in E. Coli.

Uniprot:

P08670(VIME_HUMAN) >>Visit HPA database.

Gene(ID):

VIM(7431)

Expression:

P08670 VIME_HUMAN:

Highly expressed in fibroblasts, some expression in T- and B-lymphocytes, and little or no expression in Burkitt's lymphoma cell lines. Expressed in many hormone-independent mammary carcinoma cell lines.

Description:

Vimentin, also know as VIM. It is the major subunit protein of the intermediate filaments of mesenchymal cells. It is believed to be involved with the intracellular transport of proteins between the nucleus and plasma membrane. Vimentin has been implicated to be involved in the rate of steroid synthesis via its role as a storage network for steroidogenic cholesterol containing lipid droplets.

Sequence:

P08670 VIME_HUMAN:
Protein BLAST With
NCBI/
ExPASy/
Uniprot

MSTRSVSSSSYRRMFGGPGTASRPSSSRSYVTTSTRTYSLGSALRPSTSRSLYASSPGGVYATRSSAVRLRSSVPGVRLLQDSVDFSLADAINTEFKNTRTNEKVELQELNDRFANYIDKVRFLEQQNKILLAELEQLKGQGKSRLGDLYEEEMRELRRQVDQLTNDKARVEVERDNLAEDIMRLREKLQEEMLQREEAENTLQSFRQDVDNASLARLDLERKVESLQEEIAFLKKLHEEEIQELQAQIQEQHVQIDVDVSKPDLTAALRDVRQQYESVAAKNLQEAEEWYKSKFADLSEAANRNNDALRQAKQESTEYRRQVQSLTCEVDALKGTNESLERQMREMEENFAVEAANYQDTIGRLQDEIQNMKEEMARHLREYQDLLNVKMALDIEIATYRKLLEGEESRISLPLPNFSSLNLRETNLDSLPLVDTHSKRTLLIKTVETRDGQVINETSQHHDDLE

Research Backgrounds

P08670_VIME_HUMAN

Function:

Vimentins are class-III intermediate filaments found in various non-epithelial cells, especially mesenchymal cells. Vimentin is attached to the nucleus, endoplasmic reticulum, and mitochondria, either laterally or terminally.

Involved with LARP6 in the stabilization of type I collagen mRNAs for CO1A1 and CO1A2.

PTMs:

Filament disassembly during mitosis is promoted by phosphorylation at Ser-55 as well as by nestin (By similarity). One of the most prominent phosphoproteins in various cells of mesenchymal origin. Phosphorylation is enhanced during cell division, at which time vimentin filaments are significantly reorganized. Phosphorylation by PKN1 inhibits the formation of filaments. Phosphorylated at Ser-56 by CDK5 during neutrophil secretion in the cytoplasm. Phosphorylated by STK33. Phosphorylated on tyrosine residues by SRMS.

O-glycosylated during cytokinesis at sites identical or close to phosphorylation sites, this interferes with the phosphorylation status.

S-nitrosylation is induced by interferon-gamma and oxidatively-modified low-densitity lipoprotein (LDL(ox)) possibly implicating the iNOS-S100A8/9 transnitrosylase complex.

Subcellular Location:

Cytoplasm. Cytoplasm>Cytoskeleton. Nucleus matrix.

Tissue Specificity:

Family&Domains:

The central alpha-helical coiled-coil IF rod domain mediates elementary homodimerization.

The [IL]-x-C-x-x-[DE] motif is a proposed target motif for cysteine S-nitrosylation mediated by the iNOS-S100A8/A9 transnitrosylase complex.

Belongs to the intermediate filament family.

Research Fields

· Human Diseases > Infectious diseases: Viral > Epstein-Barr virus infection.

· Human Diseases > Cancers: Overview > MicroRNAs in cancer.

References

1). Psychologic Stress Drives Progression of Malignant Tumors via DRD2/HIF1α Signaling. CANCER RESEARCH, 2021 (PubMed: 34321238) [IF=12.5]

2). Thermosensitive hydrogel as a sustained release carrier for mesenchymal stem cell-derived extracellular vesicles in the treatment of intrauterine adhesion. Journal of nanobiotechnology, 2024 (PubMed: 39289737) [IF=10.2]

Application: WB Species: Mouse Sample:

Fig. 3 The enhanced protective effects of hydrogel-EVs complex on hEndoSCs injury. hEndoSCs were stimulated by MFT (60 µmol/L) for 24 h, followed by treatment with hydrogel, EVs, or hydrogel-EVs complex. (A) hEndoSCs viability was analyzed by MTT assay. (B) PCNA protein level was detected by WB. GAPDH served as control for normalization. (C) The mRNA level of PCNA in hEndoSCs was detected by qRT-PCR. (D) Immunofluorescence staining of PCNA in hEndoSCs, with analysis of the relative optical density of PCNA. (E) The hEndoSCs apoptosis was analyzed by flow cytometry. The proportions of Annexin V+ PI+ cells were calculated. (F) The protein and (G) mRNA levels of Vimentin in hEndoSCs were analyzed by WB and qRT-PCR. GAPDH served as control for normalization of WB. (H) Immunofluorescence staining of Vimentin in hEndoSCs. The relative optical density of Vimentin was analyzed. Data were expressed as mean ± SD. n = 5. *, p

3). Salidroside improves the hypoxic tumor microenvironment and reverses the drug resistance of platinum drugs via HIF-1α signaling pathway. EBioMedicine, 2018 (PubMed: 30396856) [IF=9.7]

Application: IHC Species: mouse Sample: tumor

Fig. 4. |Sal inhibited migration and invasion and reversed the changes in EMT biomarkers. (A–B) Cell migration was measured after treatment with various drugs for 48 h. (C–D)Representative images of Transwell cell invasion assays were obtained at 200× magnification. (E–F) Double immunofluorescence staining for E-cadherin and vimentin after treated with Sal. (G-H) The expression levels of HIF-1α in tumor tissues of subcutaneously transplanted tumor mice. Error bars represent the standard deviation of experiments performed intriplicate (*P b .05, **P b .01).

Application: IF/ICC Species: human Sample: HCC cells

4). 3D-Bioprinted Scaffolds with Precise Factor Delivery for Spinal Cord Injury Repair. ACS applied materials & interfaces, 2025 (PubMed: 40673827) [IF=8.3]

5). Deprivation of methionine inhibits osteosarcoma growth and metastasis via C1orf112-mediated regulation of mitochondrial functions. Cell death & disease, 2024 (PubMed: 38769167) [IF=8.1]

6). The interaction between UBR7 and PRMT5 drives PDAC resistance to gemcitabine by regulating glycolysis and immune microenvironment. Cell death & disease, 2024 (PubMed: 39424627) [IF=8.1]

7). Altingia chinensis petroleum ether extract suppresses NSCLC via induction of apoptosis, attenuation of EMT, and downregulation of PI3K/Akt pathway. Phytomedicine : international journal of phytotherapy and phytopharmacology, 2024 (PubMed: 39566405) [IF=7.9]

8). LAMP3-mediated epithelial-mesenchymal transition promotes the invasion and excessive proliferation of fibroblast-like synoviocytes in rheumatoid arthritis. Journal of autoimmunity, 2025 (PubMed: 39799877) [IF=7.9]

9). OC-STAMP is a potential biomarker and therapeutic target for Silicosis: an exploratory investigation. Journal of translational medicine, 2025 (PubMed: 39985047) [IF=7.4]

Application: IHC Species: Rat Sample: lung tissue

Fig. 1 SiO2 induce Silicosis. A Timeline of treatment with Silica particles (50 mg/ml) or 1 ml of sterile saline (Sham). Rats were executed on days 56, 112, and 168, respectively. B HE staining of lung tissues of rats in silica modelling group and Sham group at different periods (n = 5). B, C Masson staining and collagen content of lung tissue from rats in Silica moulding group and Sham at different periods (n = 5). B, D Immunohistochemical staining of Vimentin in lung tissues of rats in different periods in Sham group and Silicone model group (n = 5). All data were expressed as mean ± SEM. *P

Application: WB Species: Mouse Sample: MLE-12 cells

Fig. 4 OC-STAMP induces Ferroptosis in MLE-12 cells and promotes fibrosis. A Establishment and intervention of OC-STAMP overexpression cell model. B, C Flow cytometry detection of overexpression of OC-STAMP and Fer-1 interfering with reactive oxygen species expression (n = 3). D, E Scratch assay to detect overexpression of OC-STAMP and Fer-1 interfering with MLE-12 cell migration (n = 3). F–K Immunoblotting to detect overexpression of OC-STAMP and Fer-1 intervening in the expression levels of OC-STAMP, Vimentin, α-SMA, GPX4, SLC7A11 proteins in MLE-12 cells (n = 3). All data are expressed as mean ± SEM. *P

10). Up-regulation of miR-20a by HPV16 E6 exerts growth-promoting effects by targeting PDCD6 in cervical carcinoma cells. Biomedicine & Pharmacotherapy, 2018 (PubMed: 29710555) [IF=6.9]

Restrictive clause

Affinity Biosciences tests all products strictly. Citations are provided as a resource for additional applications that have not been validated by Affinity Biosciences. Please choose the appropriate format for each application and consult Materials and Methods sections for additional details about the use of any product in these publications.

For Research Use Only.
Not for use in diagnostic or therapeutic procedures. Not for resale. Not for distribution without written consent. Affinity Biosciences will not be held responsible for patent infringement or other violations that may occur with the use of our products. Affinity Biosciences, Affinity Biosciences Logo and all other trademarks are the property of Affinity Biosciences LTD.

AFfirm™ Vimentin mouse monoclonal Antibody - #BF8006